Strategic Investment Decisions in Early Assets
The Challenge
A biotechnology company interested in developing compounds for immunological and inflammatory (I+I) diseases needed to prioritize indications for development for six potential assets, based on thorough assessments of key factors including regulatory, clinical, medical, commercial, and market access considerations.
Our Solution
Created a market opportunity profiling framework for market and asset evaluation to support aligned strategic decision-making across functions.
The framework covered a comprehensive set of key topics, including disease overview, epidemiology and pathophysiology, diagnosis and treatment, current and emerging therapies, market overview, competitors, and unmet needs, key stakeholders, translational research and clinical development, global regulations, and pricing and market access.
Conducted detailed secondary research using a comprehensive set of data sources for 18 indications.
Conducted primary interviews with clinical and medical experts, payers, and patient organizations across these indications.
Summarized key insights into each of the 18 disease indications, including areas of unmet needs and potential challenges.
Constructed a robust and evidence-based roadmap outlining disease opportunity domains for each of the six assets.
Benefits to the client
Comprehensive 18 I+I Indication Evaluations: Provided in-depth information and insights on 18 I+I indications serving as a foundation for informed developmental considerations.
Informed Indication Recommendations: Offered well-founded recommendations on which indications to pursue, based on informed clinical and commercial rationale.
Empowered Strategic Investment Decisions: Equipped decision-makers with the capability to make astute strategic investment choices.